Search research articles
Contact Us
Filters
Showing results (21-30 of 34) with videos related to
Page
of 4
Sort By:
Current Medical Research and Opinion
|
August 9, 2005
Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial
R M Fleischmann, S B Cohen, L W Moreland, et al.
Annals of the Rheumatic Diseases
|
August 15, 2013
Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol
D van der Heijde, R Fleischmann, J Wollenhaupt, et al.
Annals of the Rheumatic Diseases
|
August 15, 2013
Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)
P J Mease, R Fleischmann, A A Deodhar, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
January 22, 2019
Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross-sectional analysis from the US-based Corrona Psoriasis Registry
P J Mease, J B Palmer, P Hur, et al.
Arthritis Research & Therapy
|
May 4, 2019
Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data
A Deodhar, P J Mease, I B McInnes, et al.
Annals of the Rheumatic Diseases
|
August 15, 2008
Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial
D van der Heijde, M H Schiff, J Sieper, et al.
The British Journal of Dermatology
|
April 8, 2021
The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up
M Lebwohl, A Deodhar, C E M Griffiths, et al.
Arthritis and Rheumatism
|
March 6, 2012
Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III trial
P P Tak, P J Mease, M C Genovese, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
December 4, 2014
Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial
J Sieper, R Landewé, M Rudwaleit, et al.
Annals of the Rheumatic Diseases
|
November 23, 2006
Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial
A Kavanaugh, G G Krueger, A Beutler, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 34) with videos related to
Sort By:
Page
of 4
Current Medical Research and Opinion
|
August 9, 2005
Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial
R M Fleischmann, S B Cohen, L W Moreland, et al.
Annals of the Rheumatic Diseases
|
August 15, 2013
Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol
D van der Heijde, R Fleischmann, J Wollenhaupt, et al.
Annals of the Rheumatic Diseases
|
August 15, 2013
Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)
P J Mease, R Fleischmann, A A Deodhar, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
January 22, 2019
Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross-sectional analysis from the US-based Corrona Psoriasis Registry
P J Mease, J B Palmer, P Hur, et al.
Arthritis Research & Therapy
|
May 4, 2019
Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data
A Deodhar, P J Mease, I B McInnes, et al.
Annals of the Rheumatic Diseases
|
August 15, 2008
Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial
D van der Heijde, M H Schiff, J Sieper, et al.
The British Journal of Dermatology
|
April 8, 2021
The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up
M Lebwohl, A Deodhar, C E M Griffiths, et al.
Arthritis and Rheumatism
|
March 6, 2012
Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III trial
P P Tak, P J Mease, M C Genovese, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
December 4, 2014
Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial
J Sieper, R Landewé, M Rudwaleit, et al.
Annals of the Rheumatic Diseases
|
November 23, 2006
Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial
A Kavanaugh, G G Krueger, A Beutler, et al.
Page
of 4